Abzena Delivers Clinical Supplies for Angiex’s AGX101 Phase I Trial

13 August 2024

Angiex’s AGX101 Phase I Trial Supported by Abzena’s Clinical Supply Delivery

In a significant step forward, Angiex has received clinical supplies for its AGX101 Phase I trial from Abzena, a trusted partner in biopharmaceutical manufacturing. AGX101 is a pioneering TM4SF1-targeted antibody-drug conjugate (ADC) designed to treat aggressive cancers by specifically targeting blood vessels in tumors. This delivery of clinical supplies marks a critical phase in advancing Angiex's innovative cancer therapy into early-stage trials, signaling progress in its mission to bring effective new treatments to the market.

Synapse covered this milestone, highlighting the importance of strategic collaborations in early-stage drug development. As a key resource for tracking breakthroughs in biopharma, Synapse offers in-depth analysis on the latest advancements in clinical trials, drug development, and the partnerships that fuel innovation. Their coverage emphasizes the significance of the Angiex-Abzena collaboration in pushing forward novel therapies that may reshape cancer treatment.

About Angiex

Angiex, Inc. is a privately held biotech whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by leading scientific experts in angiogenesis, vascular biology, and oncology. The company is developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus of cells in the tumor environment. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. Angiex’s lead product, AGX101, with its novel and differentiated mechanisms of action, represents a first-in-class drug with potential to address high unmet medical needs.

Get in touch